<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570205</url>
  </required_header>
  <id_info>
    <org_study_id>SDD-1002-024</org_study_id>
    <nct_id>NCT01570205</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers</brief_title>
  <official_title>The Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Male Volunteers in a Randomized, Double Blind, Placebo Controlled, Dose Escalating Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xigen SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xigen SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate safety, tolerability, and pharmacokinetics of
      XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to
      healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of XG-102</measure>
    <time_frame>1 month</time_frame>
    <description>Safety of XG-102 assessed by incidence and intensity of adverse events, clinical laboratory evaluations, vital signs, ECG, phaysical examination, ocular examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>16 time-points up to 24 hours</time_frame>
    <description>Pharmacokinetic profile will be evaluated by determination of Cmax, AUC, Half-life, Clearance , Volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>XG-102 10 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>XG-102 40 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>XG-102 80 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XG-102</intervention_name>
    <description>single intravenous infusion</description>
    <arm_group_label>XG-102 10 µg/kg</arm_group_label>
    <arm_group_label>XG-102 40 µg/kg</arm_group_label>
    <arm_group_label>XG-102 80 µg/kg</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers

          -  Age ≥ 18 to ≤ 45 years

          -  BP: 100 - 150 mm Hg systolic, 50 - 95 mm Hg diastolic and pulse rate: 50 - 100 bpm.

          -  Body mass index between 18.5 and 30.0 kg/m2 and body weight in the 50 - 100 kg range.

          -  Are able to communicate and co-operate with the Investigator and his/her staff

          -  Healthy on the basis of medical history, physical examination findings, clinical
             laboratory test results, vital sign measurements, and digital 12 lead ECG readings

          -  Written informed consent obtained

          -  Male subjects with partners of childbearing potential have to use adequate
             contraception during, and for at least the four weeks after administration of study
             medication.

        Exclusion Criteria:

          -  Heavy smokers, i.e. more than 10 cigarettes per day

          -  Participation in a clinical trial during the previous 4 weeks

          -  Loss of 500 mL blood or more during the 3 month period before the screening visit of
             the study

          -  Existence of any surgical or medical condition which might relevantly interfere with
             the subject safety, the distribution, metabolism or excretion of the drug or the study
             assessments, i.e. impaired renal or hepatic function, diabetes mellitus, thyroid
             function abnormalities including abnormal thyroid hormone values in the Screening
             evaluation, cardiovascular abnormalities, chronic symptoms of pronounced constipation
             or diarrhea or conditions associated with total or partial obstruction of the urinary
             tract.

          -  History of alcohol or drug abuse in the last 3 years.

          -  Positive results of the drug Screening.

          -  Clinically significant abnormal laboratory values at the Screening or baseline
             evaluation.

          -  A history of any serious adverse reaction or hypersensitivity to any drug or other
             medicines

          -  Presence or history of any allergy requiring acute or chronic treatment (seasonal
             allergic rhinitis which requires no treatment may be tolerated).

          -  Positive results from serology examination for HBV, HCV, HIV or tuberculosis

          -  History of serious mental disorders.

          -  Need of any prescription medication within 30 days prior to the administration of the
             drug and/or nonprescription medication within 7 days prior to the administration of
             the drug or anticipated need for any concomitant medication during the study.

          -  Volunteers who are unwilling to comply with the provisions of this protocol

          -  Symptoms of a significant (upon Investigator's medical judgment) somatic or mental
             illness in the two week period preceding drug administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Seiberling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research</name>
      <address>
        <city>Allschwil</city>
        <state>BS</state>
        <zip>4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

